DEXCOM INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $DXCM in the last 7 days.
Dexcom Inc. faces a class action lawsuit alleging weak data security led to a breach by hackers. The lawsuit claims personal and medical information was stolen and published. Dexcom acknowledges a security incident but denies specifics. The company has over 2.8 million active customers. The lawsuit seeks damages and injunctive relief.
DexCom (DXCM) shares rose following the publication of positive results from its CONNECT trial in the New England Journal of Medicine, which may support Medicare coverage for its G7 insulin pump in type 2 diabetes.
Dexcom G7 CGM technology showed significant improvement in glucose control for Type 2 diabetes patients, reducing A1C levels by 1.6% on average. The study, published in NEJM, found users spent 5 more hours daily in target glucose range. Benefits were consistent across diverse participants, including those on GLP-1 medications, according to Dexcom.
Recent DXCM coverage spans financial news, regulation and market movers.
In the last 30 days, DXCM insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($366K). The most active reporter was Brown Michael Jon, EVP Chief Legal Compliance Off, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The lawsuit could pressure Dexcom's share price as investors assess legal and compliance risks.
Clinical trial publication plus implied Medicare coverage tailwind is likely to sustain bullish repricing and raise probability of broader reimbursement.
Positive trial results likely boost Dexcom's growth outlook and may lift the stock.
Health‑data breach threat may cause share decline.
The partnership and report highlight growth opportunities in the Type 2 diabetes market, likely generating modest positive sentiment for Dexcom.
AlphAI scores every news story that mentions DXCM with an AI model for sentiment and relevance, and aggregates insider trades from DEXCOM INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Dexcom Inc. faces a class action lawsuit alleging weak data security led to a breach by hackers. The lawsuit claims personal and medical information was stolen and published. Dexcom acknowledges a security incident but denies specifics. The company has over 2.8 million active customers. The lawsuit seeks damages and injunctive relief.
2 min readDexCom (DXCM) shares rose following the publication of positive results from its CONNECT trial in the New England Journal of Medicine, which may support Medicare coverage for its G7 insulin pump in type 2 diabetes.
2 min readDexcom G7 CGM technology showed significant improvement in glucose control for Type 2 diabetes patients, reducing A1C levels by 1.6% on average. The study, published in NEJM, found users spent 5 more hours daily in target glucose range. Benefits were consistent across diverse participants, including those on GLP-1 medications, according to Dexcom.
2 min readShinyHunters claims to have breached O’Reilly Automotive and Dexcom, threatening to release data by Friday. O’Reilly operates 6,500 stores with $17.78B revenue in 2025. Dexcom serves 5M users with $4.6B revenue in 2025. Neither company has responded to requests for comment.
2 min readDexcom (DXCM) released its 2026 State of Type 2 Report, highlighting the gap in CGM awareness and access. 89% of HCPs see CGM as essential, but 55% of patients lack knowledge. Dexcom also partnered with Team Novo Nordisk as its official CGM partner, aiming to advance diabetes care and awareness.
2 min readDexCom (DXCM) promoted its CFO, Jereme Sylvain, to also serve as COO, expanding his role to include global operations and quality. The company's stock has seen volatility, with a 3.1% drop over the past week and a 30.2% gain year-to-date. Analysts suggest a fair value of $94.48, indicating a modest discount at the current price of $86.62.
2 min readDexCom (DXCM) has promoted former CFO Jereme Sylvain to the role of Chief Operating Officer. The announcement highlights a leadership change at the company, which may impact investor perception.
1 min readDexCom (DXCM) appointed Jereme Sylvain as COO and Glenn Boehnlein to its board, focusing on execution, supply chain, and capital allocation. The company projects $6.8B revenue and $1.5B earnings by 2029, with analysts expecting 11.2% yearly growth. Investors watch leadership changes for impact on expansion and execution.
2 min readDexCom (DXCM) promoted CFO Jereme Sylvain to CFO and COO, added Glenn S. Boehnlein to its board. The stock trades at $87.93, up 21.33% over 90 days and 32.15% year-to-date. Analysts estimate fair value at $94.12, with growth driven by expanded insurance coverage and global market penetration. The company trades at a P/E of 33.2x, above sector and peer averages.
2 min readAUGUSTINOS NICHOLAS sold 8,089 indirectly-held shares of DEXCOM INC (DXCM) at an average of $84.04 ($84.02–$84.04, $0.68M total) across 2 trades over 2026-09-14 to 2026-09-15 under a Rule 10b5-1 trading plan.
1 min read
